

---

# CONTENTS

<b>CONTENTS</b>	<b>iii</b>		
<b>FOREWORD</b>	<b>vii</b>		
<b>PREFACE</b>	<b>ix</b>		
<b>1 BACKGROUND FOR PARTS I AND II</b>	<b>1</b>	<b>5 TRANSCRIPTION FACTORS AND REDOX SIGNALING</b>	<b>51</b>
Development of Cancer and Characteristics of Cancer Cells	1	Introduction to Redox Reactions	51
Seven Strategies for Cancer Inhibition	2	Transcription Factors	54
Using Natural Compounds in Combination	4	Mechanisms of Redox Modulation	60
Introduction to the Compounds	5	Conclusion	61
Practical Considerations on Effective Concentrations and Scaling of Doses	8	References	62
References	10	<b>6 CELL-TO-CELL COMMUNICATION</b>	<b>67</b>
		Cell Adhesion Molecules	67
		Gap Junctions	71
		Conclusion	72
		References	72
		<b><u>PART II: CANCER AT THE LEVEL OF THE ORGANISM</u></b>	
<b><u>PART I: CANCER AT THE CELLULAR LEVEL</u></b>		<b>7 OVERVIEW OF ANGIOGENESIS</b>	<b>79</b>
<b>2 MUTATIONS, GENE EXPRESSION, AND PROLIFERATION</b>	<b>13</b>	Mechanics of Angiogenesis	79
DNA, RNA, and Gene Expression	13	Angiogenic Factors and Angiogenesis Inhibition	80
Cell Proliferation	15	Similarity of Angiogenesis in Wound Healing and Cancer	81
Mutations During Carcinogenesis and Progression	17	Wound Healing and Angiogenic Factors	81
How Natural Compounds and Chemotherapy Drugs Inhibit Proliferation	23	Conclusion	88
Cytosine Methylation and DNA: A Note on Cancer Prevention	25	References	88
Conclusion	26	<b>8 NATURAL INHIBITORS OF ANGIOGENESIS</b>	<b>91</b>
References	27	Inhibition of Angiogenic Factors	91
		Additional Natural Compounds That may Inhibit Angiogenesis	97
<b>3 RESULTS OF THERAPY AT THE CELLULAR LEVEL</b>	<b>29</b>	Conclusion	98
Cell Differentiation	29	References	98
Failure to Enter the Cell Cycle	31	<b>9 INVASION</b>	<b>105</b>
Apoptosis and Necrosis	31	Connective Tissue and the Extracellular Matrix	105
Conclusion	33	The ECM and Cancer	105
References	34	Glycosidases, Proteases, and Cancer	107
		Enzyme Inhibitors	107
<b>4 GROWTH FACTORS AND SIGNAL TRANSDUCTION</b>	<b>37</b>	Adhesion Proteins and Cancer Cell Migration	110
Proliferation and Apoptosis in Normal Cells Versus Cancer Cells	37	Conclusion	111
Growth Factors	38	References	111
Signal Transduction	39	<b>10 METASTASIS</b>	<b>113</b>
Conclusion	47	Steps of Metastasis	113
References	47	Cell Detachment and Movement into a Vessel	113

Migration Through the Circulation	114	<b>16 POLYSACCHARIDES</b>	<b>203</b>
Cell Arrest at a New Location	114	Introduction to Polysaccharides	203
Movement Out of the Vessel	116	Individual Compounds	203
Induction of Angiogenesis	116	Estimated Therapeutic and LOAEL Doses of Polysaccharides	208
Conclusion	116	Using Combinations of Polysaccharides	209
References	116	Conclusion	209
<b>11 THE IMMUNE SYSTEM</b>	<b>119</b>	References	210
Innate and Adaptive Immunity	119	<b>17 LIPIDS</b>	<b>215</b>
Antigens and Antibodies	121	Types of Dietary Fat and Their Sources	215
MHC Molecule	122	Stimulation of Cancer Progression by Saturated and Omega-6 Fatty Acids	215
Role of Cytokines in Immunity	123	Inhibition of Cancer by Omega-3 Fatty Acids	218
Role of Immune Cells in Cancer	123	Conclusion	224
Role of the Immune System in Cancer Prevention	124	References	224
Immune System in Cancer Treatment	125	<b>18 AMINO ACIDS AND RELATED COMPOUNDS</b>	<b>231</b>
Conclusion	128	Amino Acids	231
References	128	Garlic	236
<b>12 NATURAL COMPOUNDS THAT AFFECT THE IMMUNE SYSTEM</b>	<b>131</b>	Bromelain and Other Proteolytic Enzymes	239
Natural Compounds That Stimulate and/or Support the Immune System	131	Conclusion	243
Clinical Studies with Chinese Herbal Formulas	135	References	243
Natural Compounds That Suppress the Immune System	137	<b>19 FLAVONOIDS</b>	<b>251</b>
Conclusion	139	Introduction	251
References	140	Isoflavones, Flavones, and Flavonols	252
<b>PART III: CLINICAL CONSIDERATIONS</b>		Flavanols—EGCG and Related Green Tea Catechins	260
<b>13 BACKGROUND FOR PART III</b>	<b>147</b>	Anthocyanidins and Proanthocyanidins	263
Synergism	147	Conclusion	266
Estimating Effective and Safe Doses	153	References	267
Available Formulations	156	<b>20 NONFLAVONOID PHENOLIC COMPOUNDS</b>	<b>275</b>
Combination Design	157	CAPE and Propolis	275
Conclusion	159	Curcumin	278
References	160	Lignans	280
<b>14 TRACE METALS</b>	<b>163</b>	Stilbenes—Resveratrol	284
Selenium	163	Quinones	286
Iron	168	Conclusion	290
Copper	171	References	291
Conclusion	172	<b>21 TERPENES</b>	<b>297</b>
References	173	Monoterpenes	297
<b>15 VITAMIN C AND ANTIOXIDANTS</b>	<b>179</b>	Triterpenoids	300
Vitamin C	180	Saponins	304
Antioxidants	188	Sesquiterpenes	309
Conclusion	196	Conclusion	311
References	196	References	311

<b>22 LIPID-SOLUBLE VITAMINS</b>	<b>317</b>	<b>APPENDIX J: DOSE CALCULATIONS</b>	<b>445</b>
Vitamin A	317	Estimating Doses Based on Pharmacokinetic and In-vitro Data	445
Vitamin D <sub>3</sub>	322	Modifications to the Estimated Required Dose	447
Vitamin E	326	LOAEL Dose Calculation Methods	447
Melatonin	330	Dose-Dependent Bioavailability	448
Conclusion	333	Therapeutic and LOAEL Dose Estimates for Natural Compounds	449
References	334	References	484
<b>23 NATURAL COMPOUNDS, CHEMOTHERAPY, AND RADIOTHERAPY</b>	<b>343</b>	<b>APPENDIX K: SUPPLEMENTAL MATERIAL FOR CHAPTER 19</b>	<b>493</b>
Introduction	343	<b>APPENDIX L: SOFTWARE AND SERVICES</b>	<b>497</b>
Effects of Natural Compounds on Chemotherapy	347	<b>APPENDIX M: NATURAL COMPOUNDS RESEARCH FUND</b>	<b>499</b>
Effects of Natural Compounds on Radiotherapy	356	<b>ACRONYMS</b>	<b>501</b>
Drug Metabolism	358	<b>INDEX</b>	<b>503</b>
Conclusion	359		
References	359		
<b>APPENDIX A: CHEMICAL DATA ON NATURAL COMPOUNDS</b>	<b>369</b>		
<b>APPENDIX B: PHARMACOKINETICS, PHARMACODYNAMICS, AND DOSE SCALING</b>	<b>377</b>		
Pharmacokinetic Models	377		
Linking Pharmacodynamic and Pharmacokinetic Models	379		
Scaling Between Species	381		
References	383		
<b>APPENDIX C: SUPPLEMENTAL MATERIAL FOR CHAPTER 2</b>	<b>385</b>		
<b>APPENDIX D: SUPPLEMENTAL MATERIAL FOR CHAPTER 3</b>	<b>391</b>		
<b>APPENDIX E: SUPPLEMENTAL MATERIAL FOR CHAPTER 4</b>	<b>401</b>		
<b>APPENDIX F: SUPPLEMENTAL MATERIAL FOR CHAPTER 8</b>	<b>409</b>		
<b>APPENDIX G: SUPPLEMENTAL MATERIAL FOR CHAPTER 9</b>	<b>417</b>		
<b>APPENDIX H: SUPPLEMENTAL MATERIAL FOR CHAPTER 12</b>	<b>425</b>		
<b>APPENDIX I: PREDICTIVE MODELS</b>	<b>431</b>		
Free Oral Clearance (FOC) Model	431		
Total Oral Clearance (TOC) Model	433		
TOPKAT Model	435		
Oral-Intraperitoneal (ORIN) Model	437		
References	442		